Literature DB >> 16999229

The vascular endothelium in hypertension.

L E Spieker1, A J Flammer, T F Lüscher.   

Abstract

The vascular endothelium plays a fundamental role in the basal and dynamic regulation of the circulation. Thus, it has a crucial role in the pathogenesis of hypertension. A spectrum of vasoactive substances is synthesised in the endothelium; of these, nitric oxide (NO), prostacyclin (PGI2) and endothelin (ET)-1 are the most important. There is a continuous basal release of NO determining the tone of peripheral blood vessels. Systemic inhibition of NO synthesis or scavenging of NO through oxidative stress causes an increase in arterial blood pressure. Also, the renin-angiotensin-aldosterone system has a major role in hypertension as it has a direct vasoconstrictor effect and important interactions with oxygen free radicals and NO. Prostacyclin, in contrast to NO, does not contribute to the maintenance of basal vascular tone of conduit arteries, but its effect on platelets is most important. ET acts as the natural counterpart to endothelium-derived NO and has an arterial blood pressure-raising effect in man. Anti-hypertensive therapy lowers blood pressure and may influence these different mediators, thus influencing endothelial function. In summary, due to its position between the blood pressure and smooth muscle cells responsible for peripheral resistance, the endothelium is thought to be both victim and offender in arterial hypertension. The delicate balance of endothelium-derived factors is disturbed in hypertension. Specific anti-hypertensive and anti-oxidant treatment is able to restore this balance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16999229     DOI: 10.1007/3-540-36028-x_8

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  18 in total

Review 1.  Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets.

Authors:  Michel Félétou; Ralf Köhler; Paul M Vanhoutte
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  Physical (in)activity and endothelium-derived constricting factors: overlooked adaptations.

Authors:  D H J Thijssen; G A Rongen; P Smits; M T E Hopman
Journal:  J Physiol       Date:  2007-10-25       Impact factor: 5.182

Review 3.  Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.

Authors:  Ivica Grgic; Brajesh P Kaistha; Joachim Hoyer; Ralf Köhler
Journal:  Br J Pharmacol       Date:  2009-03-19       Impact factor: 8.739

4.  S-nitrosylation of beta-arrestin regulates beta-adrenergic receptor trafficking.

Authors:  Kentaro Ozawa; Erin J Whalen; Christopher D Nelson; Yuanyu Mu; Douglas T Hess; Robert J Lefkowitz; Jonathan S Stamler
Journal:  Mol Cell       Date:  2008-08-08       Impact factor: 17.970

5.  Relationship between upper limb peripheral artery stiffness using the radial artery and atherosclerotic parameters.

Authors:  Shuumarjav Uurtuya; Kazuhiko Kotani; Nobuyuki Taniguchi; Hiroaki Matsunaga; Hiroshi Kanai; Hideyuki Hasegawa; Kazuomi Kario; Shun Ishibashi; Kouichi Itoh
Journal:  J Med Ultrason (2001)       Date:  2009-07-18       Impact factor: 1.314

6.  Norepinephrine deficiency with normal blood pressure control in congenital insensitivity to pain with anhidrosis.

Authors:  Lucy Norcliffe-Kaufmann; Stuart D Katz; Felicia Axelrod; Horacio Kaufmann
Journal:  Ann Neurol       Date:  2015-03-13       Impact factor: 10.422

Review 7.  Hormonal modulation of endothelial NO production.

Authors:  Sue P Duckles; Virginia M Miller
Journal:  Pflugers Arch       Date:  2010-03-07       Impact factor: 3.657

Review 8.  Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.

Authors:  Ralf Köhler; Brajesh P Kaistha; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2010-02       Impact factor: 6.902

9.  Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).

Authors:  V M Miller; D M Black; E A Brinton; M J Budoff; M I Cedars; H N Hodis; R A Lobo; J E Manson; G R Merriam; F Naftolin; N Santoro; H S Taylor; S M Harman
Journal:  J Cardiovasc Transl Res       Date:  2009-05-22       Impact factor: 4.132

Review 10.  Targeting vascular (endothelial) dysfunction.

Authors:  Andreas Daiber; Sebastian Steven; Alina Weber; Vladimir V Shuvaev; Vladimir R Muzykantov; Ismail Laher; Huige Li; Santiago Lamas; Thomas Münzel
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.